Identification of frequent mutations in the gene encoding the serine/threonine-protein kinase B-Raf (BRAF) in melanoma [2] led to the development of targeted inhibitors with improved survival demonstrated in phase III clinical trials demonstrating improved overall survival [3]. Here, BRAF is linked to melanoma.